BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 32814169)

  • 1. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
    Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
    Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
    Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
    Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo.
    Fang EF; Zhang CZ; Wong JH; Shen JY; Li CH; Ng TB
    Cancer Lett; 2012 Nov; 324(1):66-74. PubMed ID: 22579806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
    Fan X; He L; Meng Y; Li G; Li L; Meng Y
    Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.
    Meng Y; Lin S; Liu S; Fan X; Li G; Meng Y
    PLoS One; 2014; 9(7):e101998. PubMed ID: 25003606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
    Meng Y; Liu S; Li J; Meng Y; Zhao X
    Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
    Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
    Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of osthole on ovarian cancer cells in vitro.
    Jiang G; Liu J; Ren B; Tang Y; Owusu L; Li M; Zhang J; Liu L; Li W
    J Ethnopharmacol; 2016 Dec; 193():368-376. PubMed ID: 27566206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP30 Inhibits Bladder Cancer Cell Migration and Invasion
    Zhang S; Shi Z; Pang K; He H; Chen J; Zhang Z; Zhang Q; Hao L; Han C
    DNA Cell Biol; 2020 Nov; 39(11):1948-1960. PubMed ID: 33155841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribosome-inactivating Protein MAP30 Isolated from
    Zhou Y; Yang D; Qiang Z; Meng Y; Li R; Fan X; Zhao W; Meng Y
    Recent Pat Anticancer Drug Discov; 2024; 19(2):223-232. PubMed ID: 36330636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro.
    Jiang G; Liu J; Ren B; Zhang L; Owusu L; Liu L; Zhang J; Tang Y; Li W
    J Ethnopharmacol; 2017 Jun; 205():33-40. PubMed ID: 28456578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAP30 inhibits autophagy through enhancing acetyltransferase p300 and induces apoptosis in acute myeloid leukemia cells.
    Qian S; Sun L; Li J; Wu J; Hu G; Han Y; Yu K; Zhang S
    Oncol Rep; 2016 Jun; 35(6):3705-13. PubMed ID: 27035419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Walsuronoid B induces mitochondrial and lysosomal dysfunction leading to apoptotic rather than autophagic cell death via ROS/p53 signaling pathways in liver cancer.
    Geng YD; Zhang C; Lei JL; Yu P; Xia YZ; Zhang H; Yang L; Kong LY
    Biochem Pharmacol; 2017 Oct; 142():71-86. PubMed ID: 28673807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
    Zhang LL; Ding Q; Zhan JB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Momordica charantia MAP30 and its antitumor effect on bladder cancer cells.
    Hlin H; Zhi-Guo Z; Cong-Hui H; Yan Z; Qing L; Bo J; Hou-Guang H; Jun-Jie Z; Pei-Ying Z
    Minerva Urol Nefrol; 2016 Jun; 68(3):275-81. PubMed ID: 25517785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bitter melon: a panacea for inflammation and cancer.
    Dandawate PR; Subramaniam D; Padhye SB; Anant S
    Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.